Ocugen, Inc.

NASDAQ:OCGN

Biotechnology

Healthcare
$0.74 +2.46%

+$0.03 today

Market cap
$250.82M
Beta
2.21
P/E (TTM)
-5.6
EPS (TTM)
-$0.22
52W Low $0.90High $2.73

Volume 5.83M

Average 7.51M

OCGN Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Ocugen, Inc.NASDAQ: OCGN

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development grows in line with its trailing trend

Q1 FY2026 research & development of $11.26M rose 18.1% year over year, behind the +19.1% change in trailing-twelve-month research & development. Sequentially, it rose 5.5% from the prior quarter. Over 3 fiscal years it compounded at -10.9% a year.

Context

  • Research & development amounted to 900.7% of revenue in FY2025, up 108.5 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +18.1% toward the trailing-twelve-month pace of +19.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$11.26M+5.5% QoQ
Last fiscal yearDec 2025
$39.75M+23.7% YoY
LTMMar 2026
$41.48M+19.1% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+18.1%——
1 year+23.7%——
3-year CAGR-10.9%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
39.75M USD
Year-over-year change
+23.7%
4-year CAGR
+3.2%

Research & Development vs competitors

How OCGN compares with its peers on the latest reported figures

  • OCGN's LTM Mar 2026 research & development of $41.48M is the 9th highest of the 10 companies compared; the peer median is $70.57M.
  • Its year-over-year change of +19.1% is the 4th highest of 10, against a peer median of -8.7%.
  • Research & development amounts to 928.9% of revenue for OCGN, versus a peer median of 127.5%.
OCGN Competitors Peer median
Research & Development for OCGN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALMSAlumis Inc. Common StockLTM Jun 2026$346.63M -8.7%+56.3%4685.4%
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$162.51M -21.6%+18.9%—
ADCTADC Therapeutics S.A.LTM Mar 2026$94.95M -15.8%-17.7%119.9%
NGNENeurogene Inc.LTM Mar 2026$82.4M +26.5%+16.4%—
OMEROmeros CorporationLTM Mar 2026$70.57M -39.3%-10.3%713.3%
LXRXLexicon Pharmaceuticals, Inc.LTM Mar 2026$58.28M -31.8%+5.0%83.7%
FULCFulcrum Therapeutics, Inc.LTM Mar 2026$56.78M +0.2%-9.9%—
CMPXCompass Therapeutics, Inc.LTM Mar 2026$56.29M +22.7%+23.1%—
OCGNOcugen, Inc.LTM Mar 2026$41.48M +19.1%-10.9%928.9%
LCTXLineage Cell Therapeutics, Inc.LTM Mar 2026$18.85M +49.9%+8.2%127.5%
Peer median (excluding OCGN) $70.57M-8.7%+8.2%127.5%

Competitors are the stored peer set for OCGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue02.49M6.04M4.06M4.41M
Cost of Revenue00704K1.97M2.39M
Gross Profit02.49M5.33M2.09M2.02M
Gross Margin—100.0%88.3%51.5%45.9%
Research & Development35.11M56.16M39.57M32.13M39.75M
Selling, General & Admin22.92M35.4M31.99M26.69M27.58M
Operating Expenses58.03M91.56M70.86M56.84M64.94M
Depreciation & Amortization229K480K704K1.97M2.39M
EBITDA(58.11M)(86.32M)(62.37M)(52.09M)(60.27M)
EBITDA Margin—-3469.6%-1033.4%-1284.5%-1365.7%
Operating Income(58.03M)(89.07M)(65.53M)(54.76M)(62.92M)
Operating Margin—-3580.0%-1085.7%-1350.4%-1425.7%
Interest Income01.4M2.5M1.3M922K
Interest Expense79K0005.19M
Other Income / Expenses(389K)2.27M2.45M703K(4.93M)
Income Before Tax(58.42M)(86.8M)(63.08M)(54.05M)(67.85M)
Pre-Tax Margin—-3488.9%-1045.0%-1333.0%-1537.4%
Income Tax Expense(52K)0000
Net Income(58.37M)(86.8M)(63.08M)(54.05M)(67.85M)
Net Margin—-3488.9%-1045.0%-1333.0%-1537.4%
EPS (Basic)(0.30)(0.40)(0.26)(0.20)(0.23)
EPS (Diluted)(0.30)(0.40)(0.26)(0.20)(0.23)
Weighted Avg Shares195.01M214.6M244.33M271M300.17M
Weighted Avg Shares (Diluted)195.01M214.6M244.33M271M300.17M

Ocugen, Inc.

NASDAQ:OCGN

Intrinsic Alpha fair value

Locked

Current Price

$0.74

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.